University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
NCT Number: NCT07475377
The goal of this clinical trial is to learn if the time an individual eats each day impacts neurological health in people with multiple sclerosis. The main questions the investigators are asking are:
1. Does meal timing affect biomarkers of neuronal health (neurofilament light chain [NfL] and BDNF) and inflammation (IL-6, IL-17, TNF-ɑ) in adults with MS. 2. Does meal timing affect expression of circadian clock genes and genes associated with autophagy in adults with MS.
Participants will be instructed to start and stop eating at specific times each day based on their group assignment and their personal schedule. They will respond to prompts sent to them on their smartphone to record the times they start and stop eating each day.
As a secondary goal, the study will also explore the feasibility of including translocator protein (TSPO)-PET imaging of neuroinflammation in future clinical trials of TRE in people with MS. To accomplish this, imaging will be completed in a subset of 8 participants at the beginning and end of the study.
Trial opening soon.
Get Notified18 year–64 year
All sexes
Interventional
Not applicable
Birmingham, Alabama, 35294, United States
The mechanisms underlying the relationship between diet and MS are not well understood. A leading theory is that diet affects disease progression and symptoms through modulation of neuroinflammation. Previous studies in participants with other conditions suggest that time restricted eating (TRE) may reduce inflammation by improving circadian rhythms. If this holds true in people with MS, it may explain how TRE improves clinical outcomes of cognitive and physical function as seen in a previous trial. It may also explain diurnal fluctuations in pain and fatigue experienced by people within MS.
Although a previous study measured the effect of TRE on physical and cognitive function, as well as pain and fatigue, it was a single arm study and did not measure the hypothesized mechanisms of action. Therefore, the purpose of this pilot study is to examine the effects of TRE on neurological, inflammatory, and circadian markers in adults with MS.
Adults with relapsing forms of MS (relapsing remitting [RRMS] or secondary progressive [SPMS], n = 22) will be randomly assigned to either a TRE group that will eat all food within an 8-hour window each day (treatment group) or a group that will eat over 12 or more hours each day for 12 weeks.
Further, investigators will assess the feasibility of using Positron Emission Tomography (PET) imaging to measure changes in neuroinflammation with TRE. This exploratory aim will be completed in a subset of participants (n=8), and will be used to finalize imaging protocols and determine feasibility of including translocator protein (TSPO)-PET imaging of neuroinflammation in future clinical trials of TRE in people with MS.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will eat all meals within 8 hours/day and fast for the remaining 16 hours/day.
Participants will eat all meals over 12 or more hours/day.
Time frame: Baseline and 12 weeks
Time frame: Baseline and 12 weeks
Time frame: Baseline and 12 weeks
Time frame: Baseline and 12 weeks
Time frame: Baseline and 12 weeks
Time frame: Baseline, 12 weeks
Change in expression of the following genes: CLOCK, PER2, BMAL1, PER1, PER2, CRY1, CRY2, REV-ERBA/NR1D1
Time frame: Baseline, 12 weeks
Change in expression of the following autophagy-related genes: LC3A, ATG5, ATG7, ATG12, LAMP2
Time frame: Baseline and 12 weeks
Time frame: Baseline, 12 weeks
Neuroinflammation will be measured with translocator protein (TSPO)-PET imaging
Contact information is provided by the study sponsor or research team.
University of Alabama at Birmingham
Other
Acronym: Meal Time MS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07731659
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Chicago, Illinois, United States
View Trial DetailsNCT07723599
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Seattle, Washington, United States
View Trial DetailsNCT07706114
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
San Francisco, California, United States
View Trial DetailsNCT07710742
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Bursa, Nilüfer, Turkey (Türkiye)
View Trial Details